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 INTRODUCTION 
 Visceral leishmaniasis (VL) is caused by protozoan para-
sites of the  Leishmania donovani complex that invade and 
multiply primarily in the spleen, liver and bone marrow. 1 The 
disease is characterized by prolonged fever, weight loss, sple-
nomegaly and pancytopenia, and carries a high risk of mor-
tality in the absence of treatment. Parasite demonstration in 
tissue smears and/or culture provides definitive diagnosis of 
VL, but generally has lower sensitivity than serologic meth-
ods. 2 Splenic aspirate has the highest sensitivity of available 
tissue sampling techniques, but carries a risk of serious hem-
orrhage and requires an experienced microscopist, limiting its 
utility for peripheral health facilities. 3 Bone marrow and lymph 
node aspirates are safer, but have substantially lower sensitiv-
ity and similar operational constraints. 2 Classically, parasites 
have been detected in tissue samples by light microscopy of 
stained slides or culture in a specialized medium. However, 
microscopy lacks sensitivity, whereas culture requires weeks 
to yield a final result and is vulnerable to bacterial contamina-
tion. In recent years, molecular techniques have been shown to 
have the highest diagnostic sensitivity in aspirate or tissue sam-
ples and to be highly specific in experienced hands. However, 
use of the polymerase chain reaction (PCR) remains largely 
restricted to referral hospitals and research centers. 4 
 Conventional serologic tests, such as the indirect immuno-
fluorescent antibody test (IFAT), have high sensitivity because 
of the presence of high levels of IgG against  Leishmania spp. 
in the serum of otherwise immunocompetent VL patients. 5, 6 
Spurred by the need for non-invasive diagnostic testing in 
the limited resource settings most affected by the disease, 
several field-applicable serologic tests have been developed 
since the 1990s. 7 The first test to be developed was the direct 
agglutination test (DAT); this test can be read visually with-
out a machine reader, but requires trained technicians, spe-
cialized reagents and plates, and initially cost $10 or more 
per test. 8, 9 The cost of DAT antigen used at the Addis Zemen 
Health Center in Ethiopia was approximately $4 per test. 
Subsequently, several immunochromatographic tests (ICTs) 
based on the recombinant K39 antigen (rK39), comprising the 
39 amino acid repeats of a kinesin-like gene from  Leishmania 
chagasi, have been validated in several leishmaniasis-endemic 
areas. 10 The ICTs require minimal equipment, can be applied 
in peripheral health posts and community settings, and range 
in price from $1.50 to $3.00. A meta-analysis of 30 studies of 
DAT and 13 studies of rK39 ICTs concluded that their over-
all diagnostic performance was good to excellent, but that 
rK39 ICTs had lower sensitivity and less consistent perfor-
mance characteristics in eastern Africa compared with other 
regions. 11– 17 Nevertheless, changes in prototypes and marketed 
tests over time as well as differences in study protocols com-
plicate comparisons. 
 This analysis used specimens collected during an investi-
gation in a new VL epidemic site in northwestern Ethiopia. 18 
Our major objective was to address a need on the part of the 
Ethiopian Ministry of Health for local validation of two com-
mercially available VL rapid tests. To address this issue, we 
evaluated the performance of four serological tests (DiaMed 
and InBios ICTs, DAT and IFAT) in two analyses: 1) in a group 
of specimens confirmed positive by  Leishmania -specific PCR 
and 2) in a latent class analysis of data from a larger group of 
specimens from suspected VL cases. In both cases, specificity 
evaluation was conducted using specimens from healthy con-
trols from the same disease-endemic area. 
 MATERIALS AND METHODS 
 Study site.   This study was conducted at the AZHC, which 
is staffed by physicians and other professionals from Médecins 
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Sans Frontières (Operational Center Barcelona-Athens). The 
AZHC is the only health care facility for diagnosis and treat-
ment of VL patients in the  weredas (districts) of Libo and 
Fogera in the highlands of the Amhara Region of northwestern 
Ethiopia. The specimens used in this analysis were collected 
during the VL epidemic investigation described in previous 
publications. 18– 20 Informed consent was obtained from all the 
adults who participated in the outbreak investigation. For 
young children, consent was obtained from parents or guard-
ians. The protocol was reviewed and approved by the Ministry 
of Health–Ethiopia, the World Health Organization (WHO)–
Ethiopia, and Centers for Disease Control and Prevention, 
and judged to be covered as an outbreak investigation. Data 
were delinked from personal identifiers prior to this analysis. 
 Patient recruitment.  Patient recruitment was carried out 
during two periods of time: 1) October 8–22, 2005, during 
a rapid outbreak assessment by local and national health 
authorities with technical support from the WHO 18 and 2) 
February 5–24, 2007, when a team of investigators returned to 
the Amhara Region to conduct a case–control study to evalu-
ate risk factors for VL in the outbreak. 20 Cases were defined 
based on the Médecins Sans Frontières VL case definition 
as modified for a malaria-endemic area, requiring fever for 
> 2 weeks, splenomegaly and/or abdominal swelling, and/or 
weight loss; malaria was ruled out based on a rapid antigen 
detection test. 21 Patients who fulfilled this case definition were 
eligible to participate as suspected VL patients. We included 
untreated patients and those being treated with antimonial 
drugs at the time of recruitment. Three patients with apparent 
antileishmanial treatment failure hospitalized for splenic aspi-
rate were also included in the study. Demographic data were 
collected from all persons. Healthy persons from two villages 
in the VL-endemic region were recruited in February 2007 to 
provide control specimens. Participants included family mem-
bers and neighbors of VL patients who had no signs or symp-
toms of VL and no history of VL. 
 Peripheral blood samples (400 μL) from all clinically sus-
pect or treated patients and healthy controls were collected in 
Multivette 600 EDTA tubes (Sarstedt AG & Co., Nümbrecht, 
Germany). Spleen aspirates (100–200 μL) from seven clini-
cally suspect patients and the three non-responding patients 
in 2005 and from 33 clinically suspect patients in 2007 were 
collected in tubes containing 200 μL of NET 10 buffer (10 mM 
NaCl, 10mM EDTA, 10 mM Tris-HCl, pH 8.0). 
 Serologic diagnosis.  All specimens were evaluated by 
using four serologic tests performed by experienced profes-
sionals blinded to the participant’s clinical status and other 
test results. 
 Fresh peripheral whole blood samples were tested at the 
AZHC by using two rK39 rapid tests (Kalazar Detect ® Rapid 
Test; InBios International Inc., Seattle, WA, and DiaMed-IT 
Leish ® ; DiaMed AG, Cressier sur Morat, Switzerland) accord-
ing to the manufacturers’ instructions. The entire process takes 
approximately 10 minutes for the Kalazar Detect ® test and 20 
minutes for the DiaMed-IT Leish ® . Whole blood or serum can 
be used for most rapid diagnostic tests. Although the manufac-
turer’s instructions specify serum for the Kalazar Detect ® test, 
there is now sufficient evidence that whole blood produces 
similar results for patients with active VL. 22 
 The DAT (ITMA-DAT/VL; Institute of Tropical Medicine, 
Antwerp, Belgium) was performed by using freeze-dried 
antigen. The titration method followed the manufacturer’s 
protocol; titers ≥ 1:3,200 were positive and DAT titers ≤ 1:400 
were negative. In the case of high clinical suspicion of VL and 
a negative DAT result, the DAT was repeated after 4–5 days. 
If the DAT titer was in the range of 1:800–1:1,600, a splenic 
aspirate was performed. 21 Splenic aspirates were also per-
formed for confirmation of VL in a group of suspected VL 
patients during the second recruitment period. The IFAT anal-
ysis on plasma samples was performed according to a standard 
method at the WHO Collaborating Center for Leishmaniasis 
in Madrid, Spain (WHO CC); the threshold titer for positivity 
was 1:80. 23 The performance of VL serologic tests is influenced 
by human immunodeficiency virus (HIV) co-infection. 23, 24 
However, routine HIV screening had not been instituted at 
the AZHC at the time of the study. 
 Parasitologic diagnosis.   Spleen aspirate smears were stained 
with Giemsa stain. Two experienced microscopists indepen-
dently examined each slide for at least one hour. Positive 
results were confirmed by examination at a magnification of 
1,000×. One hundred microliters of spleen aspirate dilution 
were inoculated in Novy-MacNeal-Nicolle (NNN) medium 
for parasite isolation. Cultures were incubated at 27°C at 
the WHO CC (first two weeks at room temperature under 
field conditions) and examined under light microscopy every 
week for promastigote forms before subculturing with fresh 
medium. Subcultures were performed for four weeks before a 
negative result was provided. 
 A  Leishmania nested PCR was performed to detect leish-
manial DNA in peripheral blood and spleen aspirate samples 
at the WHO CC. One hundred microliters of peripheral blood 
and 100 μL of spleen aspirate dilution were subjected to a 
classical phenol-chloroform DNA extraction and ethanol pre-
cipitation, and 10 μL of the extracted DNA were analyzed by 
PCR according to the method of Cruz and others . 25, 26 Standard 
quality control procedures were followed. In all assays, nega-
tive controls without DNA and controls with healthy human 
DNA were used. DNA from an estimated 10 promastigotes 
was used as the positive control in each experiment. 25, 26 
 Statistical analysis.  Data were entered into an Excel 
(Microsoft, Redmond, WA) spreadsheet and statistical analy-
sis was performed by using Epidat version 3.1 software ( http://
www.epidata.dk/ ). We first compared the performance of each 
serologic test to confirmed diagnosis based on positive results 
by PCR in peripheral blood and/or splenic aspirate. Because 
the sensitivity of PCR in peripheral blood was low, we also 
performed a separate analysis using data from all specimens 
tested by serology (DAT, IFAT and both rapid tests) and PCR 
 T able 1 
 Characteristics of participants recruited in 2005 and 2007 in Addis 




cases † (n = 125)
VL patients under 




2005, no. (%) 89 (70.6) 37 (68.5) 0 (0)
2007, no. (%) 36 (29.4) 17 (31.5) 67 (100)
Sex ‡ 
M, no. (%) 83 (71.6) 41 (75.9) 32 (48.5)
F, no. (%) 33 (28.4) 13 (24.1) 34 (51.5)
Age, years, mean (range) § 19.6 (2.4–60) 28.1 (11–60) 18.5 (3–53)
 * VL = visceral leishmaniasis. 
 †  Includes three patients who failed to respond clinically to antimonial treatment. 
 ‡  Sex data were missing for nine suspected patients with VL and one control. 
 § Age data were missing for nine suspected patients with VL and two controls. 
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in peripheral blood. Because none of the available tests for VL 
is considered to be a true gold standard, a latent class model 
was used. This model treated the true disease status as a latent 
(unobserved) variable assumed to determine the observed test 
results, and provided estimates of sensitivity and specificity for 
each test. An additional latent variable enabled conditional 
dependence between the InBios and DiaMed tests, which are 
based on the same rK39 antigen and are therefore expected 
to have correlated results. 27 Latent class analysis was per-
formed using the software BLCM: Bayes Latent Class Models 
version 1.3. 28 
 RESULTS 
 The study population included 246 participants recruited 
during the two study periods: 86 patients clinically suspected 
to have VL, 37 patients being treated for VL and 3 VL patients 
with clinically diagnosed treatment failure in October 2005, 
and 36 patients with suspect VL, 17 patients being treated 
for VL, and 67 healthy controls from a VL-endemic area in 
February 2007 ( Table 1 ). Peripheral blood specimens from 
all participants were tested by PCR. Forty splenic aspirate 
specimens were obtained from suspect VL and treatment 
failure patients and tested by microscopy, culture, and PCR. 
A total of 35 patients (all of whom were suspected clinically 
to have VL) had positive PCR results: 12 in blood and splenic 
aspirate, 9 in splenic aspirate but not blood, and 14 in blood 
from patients who had no splenic aspirate obtained ( Table 2 ). 
Thirteen PCR-positive splenic aspirate specimens were also 
positive by parasite culture and three of these by microscopy; 
no PCR-negative specimen was positive by classical parasito-
logic methods. Among the 179 patients with a clinical picture 
consistent with VL, 103 had a positive DAT titer (≥ 1:3,200). 
Three patients with negative or borderline DAT titers had 
positive results by PCR (two in blood, one in blood and splenic 
aspirate). All healthy controls from the VL-endemic area had 
negative results by blood PCR, but one person had a positive 
DAT titer. 
 In the analysis that considered the 35 specimens with posi-
tive PCR results to represent confirmed infection, the respec-
tive sensitivities were 94.3% for Kalazar Detect ® test, 91.4% 
for DiaMed-IT Leish ® and DAT, and 100% for IFAT; all tests 
showed 98.5% specificity except the DiaMed-IT Leish ® , for 
which the specificity was 94% ( Table 3 ). One healthy control 
had positive results for all serological tests and was considered 
to have a subclinical infection. 
 The latent class analysis was performed using diagnostic 
test data from all 246 specimens. Based on this analysis, the 
estimated sensitivities were 90.5%, 89%, 88.8%, and 96% for 
the Kalazar Detect ® test, DiaMed-IT Leish ® DAT, and IFAT, 
respectively ( Table 4 ). Of the serologic tests, DAT showed 
the highest estimated specificity but the lowest sensitivity. 
Peripheral blood PCR had an estimated sensitivity of 23.2% 
and was highly specific. 
 DISCUSSION 
 In the Indian subcontinent, rK39 rapid diagnostic tests are 
now widely used for routine confirmation of VL in peripheral 
health care facilities and are considered important tools in the 
ongoing elimination effort in the region. 29 These tests have 
not been as widely accepted in VL-endemic settings in east-
ern Africa, in part because of reported lower sensitivity and 
specificity in published analyses. 11, 12, 16 However, our data sug-
gest that in Ethiopia the sensitivity and specificity of the two 
most widely used rK39 rapid tests are at least as high as those 
of the DAT, and well within the acceptable range to be used as 
the first-line tool for confirmatory testing in peripheral health 
care facilities. 
 Our study had a number of limitations, most related to the 
logistical difficulties of conducting an epidemic investigation 
in a remote area. One of the most salient limitations was that 
only 35 of our VL patients had a proven molecular or parasi-
tologic diagnosis. For this reason, we performed two analyses, 
one using suspect VL cases with positive PCR results as the 
comparator for sensitivity, and the second a latent class analy-
sis that enabled us to include all specimen results. The sensi-
tivity of the PCR assay was substantially lower than that seen 
in studies in Spain. 25 , 26  The low sensitivity was likely caused 
by the lack of optimal control over conditions between speci-
men collection in rural Ethiopia and their arrival at the labo-
ratory in Madrid where molecular assays were conducted. We 
 T able 2 
 Comparative results of serologic and parasitologic tests and PCR for 
study population, Ethiopia * 
Test







Kalazar Detect 68/122 2/3 44/54 1/67
DiaMed-IT Leish 64/122 2/3 43/54 4/67
DAT 57/122 3/3 43/54 1/67
IFAT 72/122 3/3 47/54 1/67
PCR for peripheral blood 21/122 0/3 5/54 0/67
PCR for splenic aspirate 20/40 1/3 0/0 0/0
Culture for splenic aspirate 13/40 0/3 0/0 0/0
Microscopy for splenic aspirate 3/7 0/3 0/0 0/0
 * VL = visceral leishmaniasis; DAT = direct agglutination test; IFAT = indirect immuno-
fluorescent antibody test; PCR = polymerase chain reaction. 
 †  No. specimens with positive results per total number of specimens tested. 
 ‡ VL patients with persistent clinical symptoms at the end of antimonial treatment. 
 § VL patients under treatment at the time of specimen collection. 
 T able 3 
 Comparative results of serologic tests for 35 VL patients with a diagnosis confirmed by PCR in peripheral blood and/or splenic aspirate and 
67 healthy controls from the same VL-endemic area, Ethiopia * 
Result Kalazar Detect Diamed-IT Leish DAT IFAT
PCR Positive Negative Positive Negative Positive Negative Positive Negative
Positive 33 2 32 3 32 3 35 0
Negative 1 66 4 63 1 66 1 66
Sensitivity (95% CI) 94.3 (85.2–100) 91.4 (80.7–100) 91.4 (80.7–100) 100 (98.6–100)
Specificity (95% CI) 98.5 (94.9–100) 94.0 (87.6–100) 98.5 (94.9–100) 98.5 (94.9–100)
 * VL = visceral leishmaniasis; PCR = polymerase chain reaction; DAT = direct agglutination test; IFAT = indirect immunofluorescent antibody test; CI = confidence interval. 
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included 54 VL patients under treatment at the time of sam-
pling; not surprisingly, more than 90% were PCR negative. 
However, we believe that serologic results were still likely to 
be reliable because reversion to negative serologic results is 
slow in treated VL patients, taking more than a year in most 
cases. 30 
 Unfortunately, our study was conducted at a time when rou-
tine HIV testing was not available at the field site. Subsequent 
routine HIV testing demonstrated that 18% of adult VL 
patients treated at the AZHC in 2007 had co-infection with 
HIV; the prevalence in the general population was estimated 
to be 2.1%. 31 In data from Europe, HIV–VL co-infected 
patients had low and even negative antibody titers against 
 Leishmania . 23 A prior study in Ethiopia demonstrated that 
the DAT remained reasonably sensitive (89%) whereas the 
sensitivity of DiaMed-IT Leish ® was 77% in specimens from 
HIV–VL co-infected patients. 24 Nevertheless, because the pres-
ence of a substantial number of undiagnosed HIV-co-infected 
patients in our study would lead to an underestimate of test 
sensitivity, our current estimates may in that case represent 
a lower bound for HIV-negative patients. Fortunately, HIV 
screening is now much more widely available for VL patients 
in Ethiopia, which enables a more informed interpretation of 
rapid test results for these patients. 
 The results of our analysis differ from earlier reports. The 
meta-analysis published in 2006 estimated the overall sensitiv-
ity and specificity of the rK39 ICTs at 93.9% (95% confidence 
interval [CI] = 87.7–97.1%) and 95.3% (95% CI = 88.8–
98.1%), respectively. However, in studies in eastern Africa, the 
estimated sensitivity and specificity were only 79% (95% CI = 
46.7–94.2%) and 85.2% (95% CI = 28.2–98.8%). 11 In both of 
our analyses, the two rK39 ICTs had equivalent sensitivity to 
DAT with specificities above 90%. Estimates of ICT perfor-
mance in eastern Africa combine data across a region known 
for genetic heterogeneity of  L. donovani (in marked contrast 
to the Indian sub-continent where the parasites that cause 
VL are remarkably homogeneous and rK39 rapid test per-
formance is consistently excellent). 11, 12, 32, 33 The performance 
of serologic tests may vary depending on the characteris-
tics of the circulating parasites, differences in the popula-
tions tested, and the rapid test formulations. The ability to 
make most VL diagnoses without the need for specialized 
equipment or invasive procedures makes these tests a major 
advance for peripheral health care facilities. We believe that 
our data form the basis for recommending the use of an rK39 
ICT as the first-line test to confirm VL in patients meeting 
the appropriate case definition in rural Ethiopia. 
 Received April 21, 2010. Accepted for publication June 16, 2010. 
 Acknowledgments:  We thank José Miguel Rubio and Margriet den 
Boer for helpful comments on the text and the Agencia Española de 
Cooperación Internacional for supporting this study. 
 Authors’ addresses: Carmen Cañavate, Javier Nieto, Israel Cruz, and 
Carmen Chicharro, World Health Organization Collaborating Center 
for Leishmaniasis, National Center of Microbiology, Instituto de 
Salud Carlos III, Madrid, Spain, E-mails: ccanave@isciii.es, fjnieto@
isciii.es, cruzi@isciii.es, and cchichar@isciii.es. Merce Herrero, Disease 
Prevention and Control Programmes, World Health Organization, 
Addis Ababa, Ethiopia and Médecins Sans Frontières-Ethiopia, 
Operational Centre Barcelona-Athens, Addis Zemen, Ethiopia, E-mail: 
herreromerce@gmail.com. Pilar Aparicio, National Center of Tropical 
Medicine, Instituto de Salud Carlos III, Madrid, Spain, E-mail: papari
cio@isciii.es. Abate Mulugeta and Daniel Argaw, Disease Prevention 
and Control Programmes, World Health Organization, Addis Ababa, 
Ethiopia, E-mails: abatem@et.afro.who.int and daniel@who.int. Anna J. 
Blackstock, Division of Parasitic Diseases and Malaria, Center for 
Global Health, Centers for Disease Control and Prevention, Atlanta, 
GA and Atlanta Research and Education Foundation, Decatur, GA, 
E-mail: hyp9@cdc.gov. Jorge Alvar, Department for the Control of 
Neglected Tropical Diseases, Leishmaniasis Control Program, World 
Health Organization, Geneva, Switzerland, E-mail: alvarj@who.int. 
Caryn Bern, Division of Parasitic Diseases and Malaria, Center for 
Global Health, Centers for Disease Control and Prevention, Atlanta, 
GA, E-mail:  cxb9@cdc.gov . 
 REFERENCES 
  1.  Jeronimo  SM ,  de Queiroz Sousa  A ,  Pearson  RD ,  2006 . 
 Leishmaniasis .  Guerrant  RL ,  Walker  DH ,  Weller  PF , eds. 
 Tropical Infectious Diseases: Principles, Pathogens and Practice . 
 Edinburgh, Scotland :  Churchill Livingstone Elsevier , 
 1095 – 1113 . 
  2.  Zijlstra  EE ,  Ali  MS ,  el-Hassan  AM ,  el-Toum  IA ,  Satti  M ,  Ghalib 
 HW ,  Kager  PA ,  1992 .  Kala-azar: a comparative study of parasi-
tological methods and the direct agglutination test in diagnosis . 
 Trans R Soc Trop Med Hyg  86:  505 – 507 . 
  3.  Sundar  S ,  Rai  M ,  2002 .  Laboratory diagnosis of visceral leishma-
niasis .  Clin Diagn Lab Immunol  9:  951 – 958 . 
  4.  Reithinger  R ,  Dujardin  JC ,  2007 .  Molecular diagnosis of leishma-
niasis: current status and future applications .  J Clin Microbiol 
 45:  21 – 25 . 
  5.  Pedras  MJ ,  de Gouvea Viana  L ,  de Oliveira  EJ ,  Rabello  A ,  2008 . 
 Comparative evaluation of direct agglutination test, rK39 and 
soluble antigen ELISA and IFAT for the diagnosis of visceral 
leishmaniasis .  Trans R Soc Trop Med Hyg  102:  172 – 178 . 
  6.  Gatti  S ,  Gramegna  M ,  Klersy  C ,  Madama  S ,  Bruno  A ,  Maserati  R , 
 Bernuzzi  AM ,  Cevini  C ,  Scaglia  M ,  2004 .  Diagnosis of visceral 
leishmaniasis: the sensitivities and specificities of traditional 
methods and a nested PCR assay .  Ann Trop Med Parasitol  98: 
 667 – 676 . 
  7.  Salotra  P ,  Singh  R ,  2005 .  Rapid and reliable diagnostic tests for 
visceral leishmaniasis .  Indian J Med Res  122:  464 – 467 . 
  8.  Harith  AE ,  Kolk  AH ,  Kager  PA ,  Leeuwenburg  J ,  Faber  FJ ,  Muigai 
 R ,  Kiugu  S ,  Laarman  JJ ,  1987 .  Evaluation of a newly developed 
direct agglutination test (DAT) for serodiagnosis and sero-epi-
demiological studies of visceral leishmaniasis: comparison with 
IFAT and ELISA .  Trans R Soc Trop Med Hyg  81:  603 – 606 . 
  9.  Bern  C ,  Jha  SN ,  Joshi  AB ,  Thakur  GD ,  Bista  MB ,  2000 .  Use of the 
recombinant K39 dipstick test and the direct agglutination test 
in a setting endemic for visceral leishmaniasis in Nepal .  Am J 
Trop Med Hyg  63:  153 – 157 . 
 10.  Chappuis  F ,  Sundar  S ,  Hailu  A ,  Ghalib  H ,  Rijal  S ,  Peeling  RW , 
 Alvar  J ,  Boelaert  M ,  2007 .  Visceral leishmaniasis: what are the 
needs for diagnosis, treatment and control?  Nat Rev Microbiol 
 5:  873 – 882 . 
 11.  Chappuis  F ,  Rijal  S ,  Soto  A ,  Menten  J ,  Boelaert  M ,  2006 .  A meta-
analysis of the diagnostic performance of the direct agglutina-
tion test and rK39 dipstick for visceral leishmaniasis .  BMJ 
 333:  723 . 
 12.  Boelaert  M ,  El-Safi  S ,  Hailu  A ,  Mukhtar  M ,  Rijal  S ,  Sundar  S , 
 Wasunna  M ,  Aseffa  A ,  Mbui  J ,  Menten  J ,  Desjeux  P ,  Peeling  RW , 
 T able 4 
 Sensitivity and specificity for five VL diagnostic tests for 246 partici-
pants, Ethiopia * 
Test






Kalazar Detect 90.5 84.0–95.2 90.7 84.3–95.5
DiaMed-IT Leish 89.0 81.7–94.3 91.0 85.1–95.3
DAT 88.8 81.5–94.3 97.4 93.3–99.4
IFAT 96.0 90.8–98.8 89.6 83.1–94.5
PCR for peripheral blood 23.2 16.3–31.4 99.5 97.2–100
 * VL = visceral leishmaniasis; DAT = direct agglutination test; IFAT = indirect immuno-
fluorescent antibody test; PCR = polymerase chain reaction. Estimates and credible intervals 
are based on Bayesian latent class analysis assuming pairwise correlation between InBios and 
DiaMed rK39 rapid tests. 
106 CAÑAVATE AND OTHERS
 2008 .  Diagnostic tests for kala-azar: a multi-centre study of the 
freeze-dried DAT, rK39 strip test and KAtex in east Africa and 
the Indian subcontinent .  Trans R Soc Trop Med Hyg  102:  32 – 40 . 
 13.  Chappuis  F ,  Mueller  Y ,  Nguimfack  A ,  Rwakimari  JB ,  Couffignal  S , 
 Boelaert  M ,  Cavailler  P ,  Loutan  L ,  Piola  P ,  2005 .  Diagnostic 
accuracy of two rK39 antigen-based dipsticks and the formol 
gel test for rapid diagnosis of visceral leishmaniasis in north-
eastern Uganda .  J Clin Microbiol  43:  5973 – 5977 . 
 14.  Veeken  H ,  Ritmeijer  K ,  Seaman  J ,  Davidson  R ,  2003 .  Comparison 
of an rK39 dipstick rapid test with direct agglutination test and 
splenic aspiration for the diagnosis of kala-azar in Sudan .  Trop 
Med Int Health  8:  164 – 167 . 
 15.  Zijlstra  EE ,  Nur  Y ,  Desjeux  P ,  Khalil  EA ,  El-Hassan  AM ,  Groen  J , 
 2001 .  Diagnosing visceral leishmaniasis with the recombinant 
K39 strip test: experience from the Sudan .  Trop Med Int Health 
 6:  108 – 113 . 
 16.  Diro  E ,  Techane  Y ,  Tefera  T ,  Assefa  Y ,  Kebede  T ,  Genetu  A , 
 Kebede  Y ,  Tesfaye  A ,  Ergicho  B ,  Gebre-Yohannes  A , 
 Mengistu  G ,  Engers  H ,  Aseffa  A ,  Desjeux  P ,  Boelaert  M ,  Hailu 
 A ,  2007 .  Field evaluation of FD-DAT, rK39 dipstick and 
KATEX (urine latex agglutination) for diagnosis of visceral 
leishmaniasis in northwest Ethiopia .  Trans R Soc Trop Med 
Hyg  101:  908 – 914 . 
 17.  Ritmeijer  K ,  Melaku  Y ,  Mueller  M ,  Kipngetich  S ,  O’Keeffe  C , 
 Davidson  RN ,  2006 .  Evaluation of a new recombinant K39 
rapid diagnostic test for Sudanese visceral leishmaniasis .  Am J 
Trop Med Hyg  74:  76 – 80 . 
 18.  Alvar  J ,  Bashaye  S ,  Argaw  D ,  Cruz  I ,  Aparicio  P ,  Kassa  A , 
 Orfanos  G ,  Parreño  F ,  Babaniyi  O ,  Gudeta  N ,  Cañavate  C ,  Bern 
 C ,  2007 .  Kala-azar outbreak in Libo Kemkem, Ethiopia: epide-
miologic and parasitologic assessment .  Am J Trop Med Hyg  77: 
 275 – 282 . 
 19.  Herrero  M ,  Orfanos  G ,  Argaw  D ,  Mulugeta  A ,  Aparicio  P , 
 Parreño  F ,  Bernal  O ,  Rubens  D ,  Pedraza  J ,  Lima  MA , 
 Flevaud  L ,  Palma  PP ,  Bashaye  S ,  Alvar  J ,  Bern  C ,  2009 .  Natural 
history of a visceral leishmaniasis outbreak in highland Ethiopia . 
 Am J Trop Med Hyg  81:  373 – 377 . 
 20.  Bashaye  S ,  Nombela  N ,  Argaw  D ,  Mulugeta  A ,  Herrero  M ,  Nieto  J , 
 Chicharro  C ,  Cañavate  C ,  Aparicio  P ,  Velez  ID ,  Alvar  J ,  Bern  C , 
 2009 .  Risk factors for visceral leishmaniasis in a new epidemic 
site in Amhara Region, Ethiopia .  Am J Trop Med Hyg  81: 
 34 – 39 . 
 21.  Medecins sans Frontieres -Holland ,  2006 .  MSF Manual for the 
Diagnosis and Treatment of Visceral Leishmaniasis (Kala Azar) 
under Field Conditions .  Amsterdam, The Netherlands :  MSF-
Holland . 
 22.  Boelaert  M ,  Bhattacharya  S ,  Chappuis  F ,  El Safi  S ,  Hailu  A , 
 Mondal  D ,  Rijal  S ,  Sundar  S ,  Wasunna  M ,  Peeling  R ,  2007 . 
 Evaluation of rapid diagnostic tests: visceral leishmaniasis .  Nat 
Rev Microbiol  5:  S30 – S39 . 
 23.  Medrano  FJ ,  Cañavate  C ,  Leal  M ,  Rey  C ,  Lissen  E ,  Alvar  J ,  1998 . 
 The role of serology in the diagnosis and prognosis of visceral 
leishmaniasis in patients coinfected with human immunodefi-
ciency virus type-1 .  Am J Trop Med Hyg  59:  155 – 162 . 
 24.  ter Horst  R ,  Tefera  T ,  Assefa  G ,  Ebrahim  AZ ,  Davidson  RN , 
 Ritmeijer  K ,  2009 .  Field evaluation of rK39 test and direct 
agglutination test for diagnosis of visceral leishmaniasis in a 
population with high prevalence of human immunodeficiency 
virus in Ethiopia .  Am J Trop Med Hyg  80:  929 – 934 . 
 25.  Cruz  I ,  Chicharro  C ,  Nieto  J ,  Bailo  B ,  Cañavate  C ,  Figueras  MC , 
 Alvar  J ,  2006 .  Comparison of new diagnostic tools for manage-
ment of pediatric Mediterranean visceral leishmaniasis .  J Clin 
Microbiol  44:  2343 – 2347 . 
 26.  Cruz  I ,  Cañavate  C ,  Rubio  JM ,  Morales  MA ,  Chicharro  C , 
 Laguna  F ,  Jimenez-Mejias  M ,  Sirera  G ,  Videla  S ,  Alvar  J ,  2002 . 
 A nested polymerase chain reaction (Ln-PCR) for diagnosing 
and monitoring  Leishmania infantum infection in patients co-
infected with human immunodeficiency virus .  Trans R Soc Trop 
Med Hyg  96  (Suppl 1) :  S185 – S189 . 
 27.  Dendukuri  N ,  Hadgu  A ,  Wang  L ,  2009 .  Modeling conditional 
dependence between diagnostic tests: a multiple latent variable 
model .  Stat Med  28:  441 – 461 . 
 28.  Dendukuri  N ,  Bélisle  P ,  Joseph  L ,  2007 .  BayesLatentClassModels: 
A Program for Estimating Diagnostic Test Properties and 
Disease Prevalence (Version 1.0) . 
 29.  Thakur  CP ,  Meenakshi Thakur  AK ,  Thakur  S ,  2009 .  Newer strate-
gies for the kala-azar elimination programme in India .  Indian J 
Med Res  129:  102 – 104 . 
 30.  Bern  C ,  Haque  R ,  Chowdhury  R ,  Ali  M ,  Kurkjian  KM ,  Vaz  L , 
 Amann  J ,  Wahed  MA ,  Wagatsuma  Y ,  Breiman  RF ,  Williamson  J , 
 Secor  WE ,  Maguire  JH ,  2007 .  The epidemiology of visceral leish-
maniasis and asymptomatic leishmanial infection in a highly 
endemic Bangladeshi village .  Am J Trop Med Hyg  76:  909 – 914 . 
 31.  Federal Ministry of Health of Ethiopia ,  2007 .  Single Point HIV 
Prevalence Estimate .  Adama, Ethiopia :  Federal Ministry of 
Health of Ethopia . 
 32.  Kuhls  K ,  Keilonat  L ,  Ochsenreither  S ,  Schaar  M ,  Schweynoch  C , 
 Presber  W ,  Schonian  G ,  2007 .  Multilocus microsatellite typing 
(MLMT) reveals genetically isolated populations between and 
within the main endemic regions of visceral leishmaniasis . 
 Microbes Infect  9:  334 – 343 . 
 33.  Alam  MZ ,  Kuhls  K ,  Schweynoch  C ,  Sundar  S ,  Rijal  S , 
 Shamsuzzaman  AK ,  Raju  BV ,  Salotra  P ,  Dujardin  JC ,  Schonian 
 G ,  2009 .  Multilocus microsatellite typing (MLMT) reveals 
genetic homogeneity of  Leishmania donovani strains in the 
Indian subcontinent .  Infect Genet Evol  9:  24 – 31 . 
